MBX Biosciences (MBX) Other Non-Current Assets (2023 - 2026)
MBX Biosciences (MBX) posted Other Non-Current Assets of $200000.0 for Q1 2026, up 300.0% sequentially from $50000.0 in Q3 2025, and up 300.0% YoY from $50000.0 in Q1 2025.
MBX Biosciences (MBX) Other Non-Current Assets (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Other Non-Current Assets for 4 years, with the latest figure at $200000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 300.0% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200000.0 (up 300.0% YoY) and the FY2024 annual result came in at $50000.0, changed 0.0% from the prior year.
- Other Non-Current Assets rose to $200000.0 in Q1 2026 per MBX's latest filing, from $50000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $200000.0 in Q1 2026 and troughed at $50000.0 in Q4 2023.
- A 4-year average of $71428.6 and a median of $50000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets changed 0.0% in 2024, then soared 300.0% in 2026.
- Over 4 years, Other Non-Current Assets stood at $50000.0 in 2023, then changed by 0.0% to $50000.0 in 2024, then changed by 0.0% to $50000.0 in 2025, then jumped by 300.0% to $200000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $200000.0, $50000.0, and $50000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | 625,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 625,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Dec 31, 2023 | 50,000.00 |